TP53 DNA Binding Domain Mutation

CI-VAR-00000619Explore in graph →CIViC 242

Curated evidence

Evidence by cancer (2 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–2 of 2 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Breast Neoplasm1
TP53 DNA Binding Domain Mutation	Tamoxifen	Predictive	B	Supports Resistance	3	accepted	EID2783 In a study 202 breast cancer patients undergoing first line tamoxifen treatment, 65 patients had mutations in TP53. Among the p53 wild type population a 66% response rate was reported, where response … (full text at CIViC) PMID 10786679 · Berns et al., 2000 · Open in CIViC	civic
Oral Cavity Squamous Cell Carcinoma1
TP53 DNA Binding Domain Mutation	(prognostic)	Prognostic	B	Supports Poor Outcome	4	accepted	EID641 Oral squamous cell carcinoma patients with TP53 mutations in the DNA binding domain (L2, L3 and the LSH motif) have significantly reduced cumulative survival when compared to patients with TP53 mutati… (full text at CIViC)

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.